Evotec and CHDI Foundation Extend Collaboration to Fight Huntington’s Disease
News Jan 19, 2010
Evotec AG has announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington’s disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$ 37.5 million in research funding over the next three years. Evotec has been providing research and innovation support to CHDI since 2006.
“As a proven leader in the field of drug discovery, Evotec continues to be an important strategic partner in our search for effective treatments for Huntington’s disease. Their integrated drug discovery capabilities are helping us advance numerous drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years” said Dr Robert Pacifici, Chief Scientific Officer of CHDI.
The extension of this collaboration is a further validation of Evotec’s expertise in CNS drug discovery and development. Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography. Evotec has made a significant investment to put together an integrated platform to provide drug discovery solutions, especially within the area of neuroscience.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are delighted that CHDI has chosen to further extend our strategic alliance. We view this as an important step in our work with CHDI to develop novel therapies for Huntington’s disease and meet this urgent medical need. At the same time it will allow Evotec to gain further experience in defining the underlying mechanisms of other neurodegenerative diseases.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018